According to the report titled ‘Prenatal and New-born Genetic Testing Market Size By Technology (Screening {Chorionic Villus Sampling, Maternal Serum Screening, Amniocentesis, Non-invasive Prenatal Testing}, Diagnostic {mmPCR, Spectrophotometer, FISH, Assays), By Disease (Downs Syndrome, Phenylketonuria, Cystic Fibrosis, Sickle Cell Anemia), By End-use (Hospitals, Maternity & Specialty Clinics, Diagnostic Centers), COVID-19 Impact Analysis, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027’, available with MarketStudyReport, global prenatal and new-born genetic testing market is projected to exhibit substantial growth during the forecast period 2021-2027.

 

High number of favorable initiatives by the government, increased adoption of non-invasive prenatal testing, as well as rising consumer awareness about the benefits of early detection & treatment of genetic disorders are propelling growth of global prenatal and new-born genetic testing market.

 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/1130963/

 

Additionally, high prevalence of consanguineous relationships, resulting in genetic disorders and chromosomal abnormalities in offspring is furthering aiding the industry outlook.

 

However, determinants such as rising false-positive rate for prenatal tests, lack of advanced infrastructure and skilled professionals, and ethical concerns about prenatal testing & newborn genetic screening may impede the industry growth in the forthcoming years.

 

Based on technology, screening segment held a significant industry share in 2020 and is expected to be worth USD 6.1 billion by the year 2027. Preference for minimally invasive prenatal testing over invasive genetic testing due to the complications associated with the latter is likely to drive segmental growth throughout the forecast period.

 

In terms of disease, phenylketonuria segment of global prenatal and new-born genetic testing market is projected to generate USD 1 billion by 2027. High prevalence of this disease, combined with government initiatives to promote screening and diagnostics for phenylketonuria early detection, is predicted to fuel segmental growth over the analysis period. 

 

Based on end-use, maternity & specialty clinics segment is anticipated to grow rapidly, reaching a valuation of USD 3.2 billion by the end of forecast period. Increasing prenatal mortality rate, surge in preterm births, and rising demand for prenatal care are responsible for noticeable segmental share.

 

On a regional scale, Middle East & Africa market was valued at USD 80 million in 2020 and is expected to grow significantly between 2021 and 2027. Increasing prevalence of birth defects among newborns, coupled with rising frequency of chromosomal abnormalities in the fetus across the region are expected to drive the regional market growth through 2027.

 

The competitive landscape of global prenatal and new-born genetic testing market includes companies like The BGI Group, Abbott Healthcare Private Limited, Sequenom Inc., Agilent Technologies Inc., Laboratory Corporation of America Holdings (Labcorp), Ariosa Diagnostics Inc., Biocartis Group N.V., AutoGenomics, Progenity Inc., Bio-Rad Laboratories Inc., Baebies Inc., Berry Genomics Co. Ltd, PerkinElmer Inc., Illumina Inc., and Natera Inc. among others.